Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.

Kauke MJ, Tisdale AW, Kelly RL, Braun CJ, Hemann MT, Wittrup KD.

Mol Cancer Ther. 2018 Aug;17(8):1773-1780. doi: 10.1158/1535-7163.MCT-17-0645. Epub 2018 May 2.


Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library.

Traxlmayr MW, Kiefer JD, Srinivas RR, Lobner E, Tisdale AW, Mehta NK, Yang NJ, Tidor B, Wittrup KD.

J Biol Chem. 2016 Oct 21;291(43):22496-22508. Epub 2016 Aug 30.


Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.

Schmidt MM, Townson SA, Andreucci AJ, King BM, Schirmer EB, Murillo AJ, Dombrowski C, Tisdale AW, Lowden PA, Masci AL, Kovalchin JT, Erbe DV, Wittrup KD, Furfine ES, Barnes TM.

Structure. 2013 Nov 5;21(11):1966-78. doi: 10.1016/j.str.2013.08.022. Epub 2013 Oct 10.


Developing U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences.

Paradise J, Wolf SM, Kuzma J, Kuzhabekova A, Tisdale AW, Kokkoli E, Ramachandran G.

J Law Med Ethics. 2009 Winter;37(4):688-705. doi: 10.1111/j.1748-720X.2009.00441.x.


Evaluating oversight of human drugs and medical devices: a case study of the FDA and implications for nanobiotechnology.

Paradise J, Tisdale AW, Hall RF, Kokkoli E.

J Law Med Ethics. 2009 Winter;37(4):598-624. doi: 10.1111/j.1748-720X.2009.00434.x.


Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide.

Garg A, Tisdale AW, Haidari E, Kokkoli E.

Int J Pharm. 2009 Jan 21;366(1-2):201-10. doi: 10.1016/j.ijpharm.2008.09.016. Epub 2008 Sep 19.


Exploring emerging nanobiotechnology drugs and medical devices.

Paradise J, Diliberto GM, Tisdale AW, Kokkoli E.

Food Drug Law J. 2008;63(2):407-20. No abstract available.


Supplemental Content

Loading ...
Support Center